SLS 3D Printing Amorphous Drug Conversion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing amorphous solid dispersions using selective laser sintering (SLS) 3D printing do not consistently achieve complete amorphous conversion of poorly soluble drugs, leading to unpredictable release behavior and stability issues due to partial amorphous conversion and trace crystallinity.
Innovation Solution
The use of electromagnetic energy-absorbing excipients in combination with specific printing parameters, such as controlled surface and chamber temperatures, hatch spacing, and laser speed, to achieve at least 75% of the active pharmaceutical ingredient in an amorphous form during the SLS 3D printing process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If selective laser sintering is used to prepare amorphous solid dispersions, then solubility enhancement is achieved, but complete amorphous conversion is not consistently achieved leading to trace crystallinity
Solution Approach 1:
The patent systematically optimizes laser processing parameters including laser power (2-10 W), scan speed (50-200 mm/s), hatch spacing (0.05-0.1 mm), and layer thickness (50-100 μm) to achieve complete amorphous conversion. By adjusting these parameters, the energy density delivered to the pharmaceutical composition is controlled to ensure full amorphous transformation without residual crystallinity, resolving the contradiction between achieving complete conversion and maintaining process stability.
Solution Approach 2:
The patent employs real-time monitoring and feedback control during the laser sintering process to maintain optimal processing conditions. Process parameters are dynamically adjusted based on feedback from the system to ensure complete amorphous conversion is achieved consistently, preventing trace crystallinity while maintaining stable amorphous state formation.
2Reliability
If amorphous conversion is increased to improve solubility, then bioavailability enhancement is achieved, but stability upon storage is compromised due to enhanced reactivity
Solution Approach 1:
The patent creates amorphous solid dispersions by dispersing the amorphous drug within a polymeric matrix material. The polymer acts as a stabilizing medium that physically constrains the highly reactive amorphous drug molecules, preventing their tendency to recrystallize or form hydrates/solvates during storage. This composite structure maintains the solubility advantages of the amorphous state while providing the storage stability of the crystalline state, resolving the contradiction between solubility enhancement and storage stability.
3Manufacturing precision
If laser power is increased to achieve complete amorphous conversion, then manufacturing precision is improved, but drug degradation may occur due to excessive heat
Solution Approach 1:
The patent employs dynamic control of laser parameters during processing, adjusting laser power, scan speed, and hatch spacing to optimize energy delivery. The system dynamically balances the need for sufficient energy to achieve complete amorphous conversion against the risk of excessive heat causing drug degradation. By optimizing the combination of parameters rather than simply increasing power, the process achieves complete conversion while maintaining drug stability.
Solution Approach 2:
The patent performs preliminary optimization of laser processing parameters before full-scale manufacturing. Through pre-studies and parameter optimization, the optimal combination of laser power, scan speed, and hatch spacing is determined to achieve complete amorphous conversion at the lowest necessary energy input, preventing drug degradation while ensuring complete conversion. This preliminary action establishes the optimal parameter set that resolves the contradiction between conversion completeness and drug stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in stable and predictable solubility and bioavailability enhancement by ensuring complete amorphous conversion of drugs, improving their dissolution profile and stability in pharmaceutical compositions.
Implementation Method 1
sintering the composition using a laser in an additive manufacturing process
Implementation Method 2
Selective laser sintering three-dimensional printing (SLS-3DP)
Implementation Method 3
pharmaceutical compositions that comprise an electromagnetic energy absorbing excipient
Data Source
AI summary
The present disclosure provides pharmaceutical compositions prepared using an additive manufacturing process where the active pharmaceutical ingredient has been rendered into the amorphous form or prepared as an amorphous solid dispersion at a temperature below the melting point of the active pharmaceutical ingredient or the glass transition of the physical mixture or composition of the individual components. The present disclosure also provides methods of preparing these compositions by using properties such as the chamber and surface temperature and the electron laser density.